Unknown

Dataset Information

0

Impact of disease-modifying therapies on humoral and cellular immune-responses following SARS-CoV-2 vaccination in MS patients.


ABSTRACT: The impact of distinct disease-modifying therapies (DMTs) on severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) vaccination efficacy in patients with multiple sclerosis (MS) is still enigmatic. In this prospective comparative study, we investigated humoral and cellular immune-responses in patients with MS receiving interferon beta, natalizumab, and ocrelizumab pre-vaccination and 6 weeks post second SARS-CoV-2 vaccination. Healthy individuals and interferon beta-treated patients generated robust humoral and cellular immune-responses. Although humoral immune responses were diminished in ocrelizumab-treated patients, cellular immune-responses were reduced in natalizumab-treated patients. Thus, both humoral and cellular immune responses should be closely monitored in patients on DMTs. Whereas patients with a poor cellular immune-response may benefit from additional vaccination cycles, patients with a diminished humoral immune-response may benefit from a treatment with SARS-CoV-2 antibodies in case of an infection.

SUBMITTER: Trumpelmann S 

PROVIDER: S-EPMC9111759 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Impact of disease-modifying therapies on humoral and cellular immune-responses following SARS-CoV-2 vaccination in MS patients.

Trümpelmann Susan S   Schulte-Mecklenbeck Andreas A   Steinberg Olga V OV   Wirth Timo T   Fobker Manfred M   Lohmann Lisa L   Lünemann Jan D JD   Wiendl Heinz H   Gross Catharina C CC   Klotz Luisa L  

Clinical and translational science 20220304 7


The impact of distinct disease-modifying therapies (DMTs) on severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) vaccination efficacy in patients with multiple sclerosis (MS) is still enigmatic. In this prospective comparative study, we investigated humoral and cellular immune-responses in patients with MS receiving interferon beta, natalizumab, and ocrelizumab pre-vaccination and 6 weeks post second SARS-CoV-2 vaccination. Healthy individuals and interferon beta-treated patients genera  ...[more]

Similar Datasets

| S-EPMC8826460 | biostudies-literature
| S-EPMC8920407 | biostudies-literature
| S-EPMC8456129 | biostudies-literature
| S-EPMC11004869 | biostudies-literature
| S-EPMC8604727 | biostudies-literature
| S-EPMC9894521 | biostudies-literature
| S-EPMC9111248 | biostudies-literature
| S-EPMC8537291 | biostudies-literature
| S-EPMC9377315 | biostudies-literature
| S-EPMC9349831 | biostudies-literature